BMS-986213 (Relatlimab-Nivolumab FDC) Clinical Trials
2 recruitingDrug
Phase 22
Showing 1–2 of 2 trials
Recruiting
Phase 2
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
Renal Cell Carcinoma, Clear Cell
M.D. Anderson Cancer Center15 enrolled5 locationsNCT06708949
Recruiting
Phase 2
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
Melanoma (Skin)
M.D. Anderson Cancer Center30 enrolled1 locationNCT05704647